← All trials
NCT05341583
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 24, 2022
- Primary completion
- Jun 1, 2025
- Completion date
- Jul 23, 2025
- First posted
- Apr 22, 2022
- Last posted
- Jul 15, 2022
- Enrollment
- 202
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Betta Pharmaceuticals Co.,Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.